title: Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.
abstract: Recent advances in the understanding of molecular mechanisms of cancer have led to the development of novel compounds that target specific cancer pathways. These drugs encompass monoclonal antibodies and tyrosine and non-tyrosine kinase inhibitors, and have been approved by the FDA and the European Medicines Agency, among others, for cancer treatment. These agents are associated with several toxic effects including potentially unacceptable gastrointestinal adverse effects. Diarrhea and hepatotoxicity, the most common adverse events experienced with these treatments, can frequently lead to treatment discontinuation and consequently decreased cancer control. We review the incidence and clinical patterns of the gastrointestinal and hepatic toxic effects induced by the main molecular-targeted therapies and propose some hypotheses for the causes of each adverse event.
authors: Institute Gustave Roussy, Villejuif, France.
authors: Yohann
authors: Y
authors: Loriot
authors: Gabriel
authors: G
authors: Perlemuter
authors: David
authors: D
authors: Malka
authors: Frédérique
authors: F
authors: Penault-Llorca
authors: Frédérique
authors: F
authors: Penault-Lorca
authors: Valérie
authors: V
authors: Boige
authors: Eric
authors: E
authors: Deutsch
authors: Christophe
authors: C
authors: Massard
authors: Jean Pierre
authors: JP
authors: Armand
authors: Jean-Charles
authors: JC
authors: Soria
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003967:Diarrhea / Q000139:chemically induced*; D004066:Digestive System Diseases / Q000139:chemically induced; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors